Laboratorios Farmaceuticos Rovi, S.A.

As of June 30, 2026, Laboratorios Farmaceuticos Rovi, S.A. carries a market capitalization of 59.94B, placing it among publicly traded companies globally. Its enterprise value stands at 59.86B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Laboratorios Farmaceuticos Rovi, S.A.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Laboratorios Farmaceuticos Rovi, S.A. has 51.14M shares outstanding.

As of June 30, 2026, Laboratorios Farmaceuticos Rovi, S.A. trades at a trailing price-to-earnings ratio of 16.22. The price-to-sales ratio is 3.88, and the price-to-book ratio stands at 4.29.

As of June 30, 2026, Laboratorios Farmaceuticos Rovi, S.A. trades at an EV/EBITDA multiple of 11.04 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.88 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 12.60 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Laboratorios Farmaceuticos Rovi, S.A. trades at an EV/FCF ratio of 16.75, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 59.86B versus a market cap of 59.94B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Laboratorios Farmaceuticos Rovi, S.A. maintains a current ratio of 2.05, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 15.02, indicating elevated leverage, while an interest coverage ratio of 68.05 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Laboratorios Farmaceuticos Rovi, S.A. posted a return on equity (ROE) of 29.30, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 23.99 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 18.55, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 24.66, useful for judging operating efficiency across full business cycles. The company generates approximately 6.94M in revenue per employee across its workforce of 2,223.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.87 indicates how many times Laboratorios Farmaceuticos Rovi, S.A. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Laboratorios Farmaceuticos Rovi, S.A. recorded 1.00B in income tax expense. That works out to an effective tax rate of 21.33, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 4.69B, leaving 3.70B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on June 18, 2026, Laboratorios Farmaceuticos Rovi, S.A.'s stock has declined approximately 6.24% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Laboratorios Farmaceuticos Rovi, S.A. generated 15.43B in revenue and converted that into 3.70B in net income, yielding earnings per share of 72.21. EBITDA reached 5.42B, while operating income came in at 3.51B.

As of June 30, 2026, Laboratorios Farmaceuticos Rovi, S.A. holds 2.56B in cash and equivalents against 2.15B in total debt, resulting in a net debt position of -2.53B. Total book value stands at 13.98B, with working capital of 5.82B providing operational flexibility.

Laboratorios Farmaceuticos Rovi, S.A. produced 5.06B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.54B in capital expenditures, free cash flow totaled 3.51B - equivalent to 68.65 per share.

Over the twelve months ended June 30, 2026, Laboratorios Farmaceuticos Rovi, S.A. posted a gross margin of 66.17, reflecting its pricing power and cost economics. The operating margin of 22.72 and net profit margin of 23.95 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Laboratorios Farmaceuticos Rovi, S.A. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 5.86, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 2.41, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Laboratorios Farmaceuticos Rovi, S.A. shareholders.

As of June 30, 2026, Laboratorios Farmaceuticos Rovi, S.A. has an Altman Z-Score of 6.74, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.